LIFS Stock Overview
Life Stem Genetics Inc., a development stage company, focuses on establishing stem cell therapy based clinics worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Life Stem Genetics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0016 |
| 52 Week High | US$0.13 |
| 52 Week Low | US$0.0001 |
| Beta | 0 |
| 1 Month Change | 6.67% |
| 3 Month Change | -38.46% |
| 1 Year Change | 166.67% |
| 3 Year Change | -71.93% |
| 5 Year Change | 159,900.00% |
| Change since IPO | -99.85% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| LIFS | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 0% | 6.5% | -3.2% |
| 1Y | 166.7% | 4.0% | 19.3% |
Return vs Industry: LIFS exceeded the US Healthcare industry which returned 2.5% over the past year.
Return vs Market: LIFS exceeded the US Market which returned 20.2% over the past year.
Price Volatility
| LIFS volatility | |
|---|---|
| LIFS Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 6.9% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LIFS's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine LIFS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | n/a | Gloria Simov | n/a |
Life Stem Genetics Inc., a development stage company, focuses on establishing stem cell therapy based clinics worldwide. Its products and services include nutraceutical and medical supplements, and IV nutritional cocktails; stem cell banking services; stem cell treatments for degenerative conditions, hyperbaric oxygen therapy, cancer treatments, and weight loss; anti-aging stem cell therapy; anti-viral therapy; and adistem stem cell treatments for orthopedics, neurological, and lung diseases. Life Stem Genetics Inc. has a strategic collaborative agreement with American CryoStem Corporation.
Life Stem Genetics Inc. Fundamentals Summary
| LIFS fundamental statistics | |
|---|---|
| Market cap | US$73.34k |
| Earnings (TTM) | US$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs LIFS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIFS income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$0 |
| Earnings | US$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did LIFS perform over the long term?
See historical performance and comparison